Enosi Life Sciences Corp. (“Enosi” or the “Company”), a drug research and development company focused on providing industry-leading therapeutics for autoimmune disease, cancer, and acute inflammation, today announced the launch of its Regulation D offering, following the filing of its Form D by the U.S. Securities and Exchange Commission.
September 29, 2020
· 3 min read